Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate cyclase type 4 (ADCY4) is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP), a key secondary messenger involved in intracellular signal transduction. ADCY4 is one of several adenylyl cyclase isoforms that mediate cellular responses to various stimuli by producing cAMP in response to activation by G protein signaling, but it is insensitive to calcium/calmodulin regulation. It is prominently expressed in olfactory cilia, suggesting a specialized role in olfactory signaling and detection of smells. Genetically, it is localized on human chromosome 14q11.2. In the context of disease, ADCY4 has been identified as a possible epigenetic biomarker and target for breast cancer. Although broad pharmacologic modulation of adenylyl cyclase activity exists, no clinically approved drugs target ADCY4 specifically.
Activation or inhibition of the enzyme results in altered cAMP production, affecting downstream cellular signaling via protein kinase A (PKA) and other cAMP-dependent pathways. G-protein coupled mechanisms (activated by G protein beta and gamma subunit complexes).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylate cyclase type 4 (ADCY4).